Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total Stock Market Index Fund ETF (VTI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Vanguard Total Stock Market Index Fund ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Vanguard Total Stock Market Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $376.6, while State Street SPDR S&P Biotech ETF trades at $159.88. Which is the better fit depends on your goals.

VTIXBI
52-Week High
$384.30$169.55
52-Week Low
$311.68$93.43
Sector
Broad Market / Factor

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total Stock Market Index Fund ETF

VTI trades at $377.60, down 0.56% with neutral technical signals. The ETF maintains broad U.S. market exposure across 3,515 stocks with a minimal 0.03% expense ratio. Recent institutional activity includes DMC Group's $794,000 investment in Q2 2026, while technical indicators show support at $375 and resistance at $379.

Long-term outlook remains positive given historical 10% annual market returns, though concentration risk exists with top ten holdings representing one-third of assets. Market sentiment favors VTI for diversification amid potential volatility, with analysts highlighting its core portfolio role for 20-year horizons.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total Stock Market Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

Read more on VTI

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI